About the Authors
- Hilda J. I. de Jong
-
Affiliations Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands, Department of Toxicogenomics, Maastricht University Medical Centre, Maastricht, Netherlands, Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
- Siti R. F. Saldi
-
Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
- Olaf H. Klungel
-
Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
- Rob J. Vandebriel
-
Affiliation Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands
- Patrick C. Souverein
-
Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
- Ronald H. B. Meyboom
-
Affiliations Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands, Uppsala Monitoring Centre, World Health Organisation Collaborating Centre for International Drug Monitoring, Uppsala, Sweden
- J. L. M. (Anneke) Passier
-
Affiliation Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, Netherlands
- Henk van Loveren
-
Affiliations Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands, Department of Toxicogenomics, Maastricht University Medical Centre, Maastricht, Netherlands
- Jan Willem Cohen Tervaert
-
* E-mail: jw.cohentervaert@maastrichtuniversity.nl
Affiliation Division of Clinical and Experimental Immunology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands
Competing Interests
The Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, employing authors HJI de Jong, SRF Saldi, OH Klungel, PC Souverein and RHB Meyboom has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, private–public funded Top Institute Pharma (www.tipharma.nl and includes co-funding from universities, government and industry) and the Dutch Medicines Evaluation Board. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Contributed to the conception of the study: JWCT. Contributed to the design of the study: HJIdJ SFRS OHK PCS JWCT. Performed the data analysis: HJIdJ SFRS. Drafted the manuscript: HJIdJ. Contributed to the interpretation of the results: OHK RHBM JWCT. Provided the background data for the study: OHK RJV PCS HvL JWCT. Provided the data: RHBM JLMP. Reviewed the manuscript: OHK RJV PCS RHBM JLMP HvL JWCT. Involved in initiating the project to which the study presented belongs: HvL JWCT. Approved of the version to be published: HJIdJ SFRS OHK RJV PCS RHBM JLMP HvL JWCT.